<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="115564">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01598753</url>
  </required_header>
  <id_info>
    <org_study_id>42444-D</org_study_id>
    <nct_id>NCT01598753</nct_id>
  </id_info>
  <brief_title>Combined Behavioral and Analgesic Trial for Fibromyalgia</brief_title>
  <acronym>COMBAT-FM</acronym>
  <official_title>Phase 3 Double Blind Randomized Study Comparing Drug Treatment (Tramadol Versus Placebo) and Behavioral Health Treatments (Cognitive Behavior Therapy Versus Health Education)for Patients With Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized control study that involves a combination of a drug treatment,
      behavioral health, and placebo controls.

      Some participants will receive a medication approved by the Food and Drug Administration for
      treatment of moderate to moderately severe pain called Tramadol HC1 IR. Others will receive
      an inactive pill, called a placebo. There will also be 2 different types of behavioral
      health treatments, Cognitive-Behavior Therapy (CBT) and Health Education (HE) both of which
      have been recommended for the treatment of patients with FM by the American Pain Society.

      There are 4 possible study treatment combinations:

        1. Tramadol + CBT,

        2. Tramadol + HE,

        3. Placebo + CBT,

        4. Placebo + HE.

      Although Tramadol, CBT, and HE have been shown to have some benefits for FM patients, there
      have been no studies that have evaluated the combination of medication and a behavioral
      health treatment. The primary purpose of this study is to compare the benefits of the 4
      combinations listed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mean pain severity derived from 5-days of daily pain diaries and change in physical function assessed from the Fibromyalgia Impact Questionnaire-Revised (FIQ-R).</measure>
    <time_frame>Baseline is one week prior to drug titration. Post treatment is assessed the week following final treatment</time_frame>
    <description>The primary outcome is the change in pain severity measured by the average of 5-days of daily pain diaries assessed just prior to and at the end of treatment.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Fibromyalgia</condition>
  <arm_group>
    <arm_group_label>Tramadol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cognitive Behavior Therapy for FM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Health Education</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tramadol</intervention_name>
    <description>50 mg tablets titrated up to 2 tablets four times per day for a maximum dose of 400mg per day.
Minimum accepted dose of 200mg per day</description>
    <arm_group_label>Tramadol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmacological inactive tablet, 50mg tablets titrated to 2 tabs per day up to 400mg</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavior Therapy for FM</intervention_name>
    <description>Subjects will be seen for 8 weekly 50 minute sessions of Cognitive Behavior Therapy that has been specifically tailored for Fibromyalgia patients.</description>
    <arm_group_label>Cognitive Behavior Therapy for FM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Health Education</intervention_name>
    <description>Subjects will receive 8 weekly 50 minute sessions of Health Education on Fibromyalgia</description>
    <arm_group_label>Health Education</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and Females 21-70

          -  Diagnosis of Fibromyalgia

          -  Current primary care physician

          -  Fluent in English

        Exclusion Criteria:

          -  Rheumatologic disorders

          -  Drug and alcohol abuse in the past year

          -  Psychiatric hospitalization in the past 6 months

          -  Current use of Tramadol

          -  Certain antidepressant and other pain medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Caitlin Sheffels</last_name>
    <phone>206-221-1737</phone>
    <email>csheff@uw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Dworkin, PhD</last_name>
      <email>Robert_Dworkin@URMC.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Dworkin, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caitlin M Sheffels, BA</last_name>
      <phone>206-221-1737</phone>
      <email>csheff@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Dennis Turk, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 1, 2015</lastchanged_date>
  <firstreceived_date>May 1, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Dennis Turk</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tramadol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
